Mark A. Varney, Ph.D.
Dr. Varney has spent over 25 years in the pharmaceutical industry. He co-founded Neurolixis and served as Chief Executive Officer for 8 years (2011-2019). Prior to Neurolixis, Dr. Varney worked at Cortex Pharmaceuticals where he was President and CEO and formerly Chief Scientific Officer and Chief Operating Officer.
Prior to joining Cortex, Dr. Varney held senior level positions at Sepracor, Inc. (now Sunovion), where he was Vice President and head of Discovery, and at Bionomics, Ltd., where he was Vice President of Drug Discovery. Dr. Varney held positions of increasing responsibilities over his six-year tenure at SIBIA Neuroscience Inc., including his most recent position as Director of Neuropharmacology. Upon the acquisition of SIBIA by Merck, Inc in 1999, he was appointed a Director at Merck’s San Diego facility.
Prior to SIBIA, Dr. Varney held research positions at Servier in France and Merck Sharp & Dohme in the U.K. Dr. Varney received his B.Sc. in Biochemistry with honors from Surrey University, U.K. and completed his Ph.D. and postdoctoral training at Oxford University, U.K. Dr. Varney’s career has focused on drug discovery programs for treating schizophrenia, depression, cognitive disorders, anxiety, pain, epilepsy and insomnia. He has been successful in developing drug candidates in several of these disease areas, and has published extensively in peer-reviewed journals and filed numerous patent applications relating to new chemical entities and methods of use.
Dr. Varney is currently Chief Scientific Officer at another biotech company, but continues to support Neurolixis programs as a Board member.